Regeneron (REGN) Misses Q1 EPS by 1c; Reaffirms
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Leerink Partners Raises Price Target on Regeneron (REGN) Following 1Q Report
May 6, 2016 9:08 AM EDTLeerink Partners reiterated an Outperform rating on Regeneron Pharma (NASDAQ: REGN), and raised the price target to $530.00 (from $523.00), following the company's 1Q earnings report. Total revenue beat consensus by 2% driven by higher collaboration revenue, and revenue grew by 38% compared to Q1 2015 and by 9% QoQ. The companys earnings fell short of consensus based on higher than expected SG&A and taxes. Pro forma EPS was $2.57 below consensus of $2.68.
Analyst Geoffrey Porges... More
Baird Cuts Price Target on Regeneron (REGN) to $505; Reiterates Outperform
May 5, 2016 3:25 PM EDTBaird maintained an Outperform rating on Regeneron Pharma (NASDAQ: REGN), and cut the price target to $505.00 (from $526.00), following the company's 1Q earnings report. EPS of $2.57 was reported in-line with expectations. Baird continues to believe that the copmant can deliver growth over the next few... More
